Of specific interest to this article, RNA therapeutics are also under development that aim to harmonize hyperinflammation (again in cancer), such as aptamer NOX-A12 and NOX-E36, which disrupt the expression of CXCL12 and CCL2, respectively. This evidence concerns the gene CXCL12 and cancer.